Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (34 ops.)
Latest filing published 02 Oct 2026 for Spyre Therapeutics, Inc., €224k.
Filing timeline
BuySaleScott L. Burrows
Insider track record
Disclosed buys
0
Disclosed sells
34
Signal history
Scott L. Burrows: trading record in brief
In 2026, Scott L. Burrows filed 33 of the 47 filings in this record, far more than in earlier years (1 to 6 a year since 2021). Filings are published from December 28, 2021 to October 2, 2026, and all 33 from 2026 fall in the last twelve months, 24 of them sales.
Burrows is Chief Financial Officer at Spyre Therapeutics, Inc. (36 filings) and, according to the record, at Arcutis Biotherapeutics, Inc. (11). No purchase; 34 sales for EUR 8,357,609, median EUR 136,121. The three largest, all at Spyre Therapeutics, Inc., date from 2026: EUR 1,406,504 on September 2, EUR 1,386,666 on September 30 and EUR 766,963 on June 25. The record also holds 10 option exercises and 3 share grants.
The median publication delay is 2 days.
At Spyre Therapeutics, Inc., 19 of Burrows's own trades fall within 30 days of a trade by Cameron Turtle and 14 by Heidy King-Jones, in the same direction. At Arcutis Biotherapeutics, Inc., Todd Franklin Watanabe has 8.
Companies and markets linked to Scott L. Burrows
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations47 total
17,500 shares@ US$14.500.0034% mcap3.1% of flowCommon StockSEC:0001636282-26-000117:0
17,500 shares@ US$89.890.021% mcap19.1% of flowCommon StockSEC:0001636282-26-000117:1
7,500 shares@ US$14.500.0015% mcap1.3% of flowCommon StockSEC:0001636282-26-000117:2
600 shares@ US$89.070.0007% mcap0.6% of flowCommon StockSEC:0001636282-26-000117:3
1,500 shares@ US$90.270.0018% mcap1.6% of flowCommon StockSEC:0001636282-26-000117:4
2,100 shares@ US$91.920.0026% mcap2.3% of flowCommon StockSEC:0001636282-26-000117:5
3,071 shares@ US$92.950.0038% mcap3.5% of flowCommon StockSEC:0001636282-26-000117:6
229 shares@ US$93.570.0003% mcap0.3% of flowCommon StockSEC:0001636282-26-000117:7
7,500 shares@ US$14.500.0014% mcap1.9% of flowCommon StockSEC:0001636282-26-000109:0
900 shares@ US$86.250.0010% mcap1.4% of flowCommon StockSEC:0001636282-26-000109:1
4,384 shares@ US$87.110.0049% mcap6.6% of flowCommon StockSEC:0001636282-26-000109:2
2,016 shares@ US$88.030.0023% mcap3.1% of flowCommon StockSEC:0001636282-26-000109:3
200 shares@ US$89.040.0002% mcap0.3% of flowCommon StockSEC:0001636282-26-000109:4
18,232 shares@ US$89.350.021% mcap28.4% of flowCommon StockSEC:0001636282-26-000109:5
100 shares@ US$97.100.0001% mcap0.2% of flowCommon StockSEC:0001636282-26-000100:3
7,500 shares@ US$14.500.0014% mcap1.9% of flowCommon StockSEC:0001636282-26-000100:0
5,100 shares@ US$95.210.0063% mcap8.5% of flowCommon StockSEC:0001636282-26-000100:1
2,300 shares@ US$96.300.0029% mcap3.9% of flowCommon StockSEC:0001636282-26-000100:2
5,000 shares@ US$87.124.6% of flowCommon StockSEC:0001853327-26-000008:1
10,000 shares@ US$87.149.1% of flowCommon StockSEC:0001853327-26-000008:2
15,000 sharesCommon StockSEC:0001853327-26-000008:0
7,500 shares@ US$14.501.9% of flowCommon StockSEC:0001636282-26-000076:0
1,801 shares@ US$69.752.2% of flowCommon StockSEC:0001636282-26-000076:1
2,599 shares@ US$70.773.2% of flowCommon StockSEC:0001636282-26-000076:2
3,100 shares@ US$72.063.9% of flowCommon StockSEC:0001636282-26-000076:3
25 of 47 declarations
